| Field | Row 1 |
|---|---|
| adsh | 0000950170-25-065765 |
| cik | 1080014 |
| name | INNOVIVA, INC. |
| sic | 2834 |
| countryba | US |
| stprba | CA |
| cityba | BURLINGAME |
| zipba | 94010 |
| bas1 | 1350 OLD BAYSHORE HIGHWAY |
| bas2 | SUITE 400 |
| baph | 6502389600 |
| countryma | US |
| stprma | CA |
| cityma | BURLINGAME |
| zipma | 94010 |
| mas1 | 1350 OLD BAYSHORE HIGHWAY |
| mas2 | SUITE 400 |
| countryinc | US |
| stprinc | DE |
| ein | 943265960 |
| former | THERAVANCE INC |
| changed | 20020207 |
| afs | 1-LAF |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250507 |
| accepted | 2025-05-07 16:31:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | inva-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0000950170-25-065765 | 20250331 | Accrued Income Taxes Noncurrent | 54061000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Accounts Payable Current | 4700000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Amortization Of Capitalized Fees And Depreciation Of Property And Equipment | 3488000.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 319090000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Cost Of Goods And Services Sold | 10971000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20241231 | Deferred Revenue Current | 1126000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Earnings Per Share Basic | 0.5800 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Income Loss From Equity Method Investments | 35342000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20250331 | Income Loss From Equity Method Investments | -13549000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20240331 | Increase Decrease In Accounts Payable | -5827000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Increase Decrease In Interest Payable Net | -2589000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Increase Decrease In Other Operating Assets | -633000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Interest Expense | 1600000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Health Care Royalty Partners; Debt Instrument= Royalty Financing Agreement; Longterm Debt Type= Loans Payable; | ||
| 0000950170-25-065765 | 20250331 | Long Term Debt Noncurrent | 256670000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20231231 | Long Term Investments | 444432000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Long Term Investments | 291100000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Net Cash Provided By Used In Operating Activities | 37047000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Net Cash Provided By Used In Operating Activities | 48617000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Operating Lease Right Of Use Asset | 2110000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Other Assets Current | 313000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Proceeds From Sale Of Property Plant And Equipment | 98000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Profit Loss | 36532000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20241231 | Profit Loss | 2600000.0000 | USD | 1 | us-gaap/2024 | Consolidated Entities= Armata Pharmaceuticals Inc; | ||
| 0000950170-25-065765 | 20250331 | Profit Loss | -46584000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20240331 | Research And Development Expense | 2229000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; Product Or Service= Internal Expenses; | ||
| 0000950170-25-065765 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 12081000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Giapreza; | ||
| 0000950170-25-065765 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 4223000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Xerava; | ||
| 0000950170-25-065765 | 20250331 | Selling General And Administrative Expense | 27491000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Share Based Compensation | 1455000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -25189000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-065765 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 627000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20240331 | Stock Issued During Period Value Share Based Compensation | 1000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20240331 | Treasury Stock Value Acquired Cost Method | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-065765 | 20240331 | Unrealized Other Gain Loss On Investments | -13335000.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 63185000.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Accounts Receivable Net | 16673000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Adjustments To Additional Paid In Capital Share Based Compensation Requisite Service Period Recognition Shares | 0.0000 | shares | 1 | 0000950170-25-065765 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-065765 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 1455000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Amortization Of Intangible Assets | 6440000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20250331 | Amortization Of Intangible Assets | 0.0000 | USD | 1 | us-gaap/2024 | Finite Lived Intangible Assets By Major Class= In Process Research And Development; | ||
| 0000950170-25-065765 | 20250331 | Capitalized Contract Cost Net | 66505000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 304964000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-065765 | 20250331 | Common Stock Shares Issued | 62771000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Current Portion Of I S P Fund Investments | 127790000.0000 | USD | 0 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20250331 | Deferred Income Tax Assets Net | 12294000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Earnings Per Share Diluted | 0.4600 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Equity Method Investment | 38744000.0000 | USD | 0 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20240331 | Gain Loss On Other Investments | -13335000.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20240331 | Gain Loss On Other Investments | -13335000.0000 | USD | 1 | 0000950170-25-065765 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20250331 | Gain Loss On Other Investments | -65299000.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20250331 | Income Tax Expense Benefit | -7995000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20240331 | Increase Decrease In Accrued Liabilities | 441000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Interest Expense | 5851000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Interest Expense | 4711000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Long Term Investments | 341664000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Net Cash Provided By Used In Investing Activities | -34674000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Operating Income Loss | 41428000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Other Assets Noncurrent | 41477000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Other Nonoperating Income Expense | -1236000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20241231 | Preferred Stock Shares Authorized | 230000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Profit Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20250331 | Profit Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20250331 | Profit Loss Shares | 0.0000 | shares | 1 | 0000950170-25-065765 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20250331 | Research And Development Expense | 3051000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; Product Or Service= External Services; | ||
| 0000950170-25-065765 | 20250331 | Retained Earnings Accumulated Deficit | -48381000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1093340000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-065765 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 633000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 11343000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-065765 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 694658000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-065765 | 20250331 | Stock Issued During Period Shares Share Based Compensation | 106000.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20240331 | Stock Issued During Period Value Share Based Compensation | 404000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Treasury Stock Shares Acquired | 0.0000 | shares | 1 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-065765 | 20250331 | Unrealized Other Gain Loss On Investments | -65299000.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 62709000.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-065765 | 20240331 | Amortization Of Acquired Intangible Assets | 6440000.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20250331 | Amortization Of Acquired Intangible Assets | 6475000.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20241231 | Amortization Of Intangible Assets | 0.0000 | USD | 4 | us-gaap/2024 | Finite Lived Intangible Assets By Major Class= In Process Research And Development; | ||
| 0000950170-25-065765 | 20240331 | Capitalized Contract Cost Amortization | 3456000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Royalty; Related Party Transactions By Related Party= G S K; | ||
| 0000950170-25-065765 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 193513000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 14126000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Common Stock Shares Authorized | 200000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Cost Of Goods And Services Sold | 10971000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product; | ||
| 0000950170-25-065765 | 20250331 | Gain Loss On Other Investments | -65299000.0000 | USD | 1 | 0000950170-25-065765 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20240331 | Increase Decrease In Accrued Income Taxes Payable | 49000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Increase Decrease In Accrued Income Taxes Payable | 2376000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Increase Decrease In Due From Related Parties Current | -4711000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Intangible Assets Net Excluding Goodwill | 208433000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Interest And Dividend Income Operating | 4538000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20240331 | Interest Expense | 2700000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Health Care Royalty Partners; Debt Instrument= Royalty Financing Agreement; Longterm Debt Type= Loans Payable; | ||
| 0000950170-25-065765 | 20250331 | Interest Expense | 4711000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20250331 | Liabilities And Stockholders Equity | 1254390000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Other Liabilities Noncurrent | 64275000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Preferred Stock Par Or Stated Value Per Share | 0.0100 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Preferred Stock Shares Authorized | 230000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Prepaid Expense And Other Assets Current | 15414000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Profit Loss | 36532000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-065765 | 20250331 | Profit Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-065765 | 20250331 | Stock Issued During Period Value Share Based Compensation | 183000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Accounts Receivable Net | 600000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Zai Lab; Type Of Arrangement= Interim Supply Agreement; | ||
| 0000950170-25-065765 | 20241231 | Accrued Liabilities And Other Liabilities | 29999000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Adjustments To Additional Paid In Capital Share Based Compensation Requisite Service Period Recognition Shares | 0.0000 | shares | 1 | 0000950170-25-065765 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20250331 | Amortization Of Intangible Assets | 6475000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Amortization Of Intangible Assets | 6475000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20241231 | Cash And Cash Equivalents At Carrying Value | 304964000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0100 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Debt Current | 192028000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Employee Related Liabilities Current | 7376000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Gain Loss On Other Investments | -59161000.0000 | USD | 4 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20250331 | Goodwill | 17905000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Gross Profit | 73315000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -38589000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Income Tax Expense Benefit | -8592000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20250331 | Increase Decrease In Accounts Payable | 2568000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Increase Decrease In Inventories | 3543000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Interest And Dividend Income Operating | 4399000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Interest And Dividend Income Operating | 4538000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Interest Paid Net | 5179000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Inventory Net | 33725000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Liabilities And Stockholders Equity | 1301060000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20231231 | Operating Income Loss | -6578000.0000 | USD | 1 | us-gaap/2024 | Consolidated Entities= Armata Pharmaceuticals Inc; | ||
| 0000950170-25-065765 | 20241231 | Operating Lease Right Of Use Asset | 2453000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Other Nonoperating Income Expense | -1236000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Other Nonoperating Income Expense | -996000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Payments To Acquire Marketable Securities | 43136000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Profit Loss Shares | 0.0000 | shares | 1 | 0000950170-25-065765 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-065765 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 2235000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Xacduro; | ||
| 0000950170-25-065765 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 4768000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Xerava; | ||
| 0000950170-25-065765 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 88632000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 18273000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Giapreza; | ||
| 0000950170-25-065765 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 7783000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Xacduro; | ||
| 0000950170-25-065765 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -393829000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-065765 | 20240331 | Stock Issued During Period Value Share Based Compensation | 403000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-065765 | 20250331 | Stock Issued During Period Value Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-065765 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 84531000.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Accrued Income Taxes Noncurrent | 53227000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 1455000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-065765 | 20240331 | Amortization Of Financing Costs And Discounts | 525000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Assets Current | 554306000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Assets Current | 582022000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Capitalized Contract Cost Net | 69961000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0100 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Common Stock Shares Outstanding | 62797000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20250331 | Common Stock Value | 628000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Debt Current | 192215000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Deferred Revenue Current | 1002000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Earnings Per Share Basic | -0.7400 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Employee Related Liabilities Current | 3789000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Gross Profit | 60088000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Income Loss From Equity Method Investments | 35342000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Interest Paid Net | 5179000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Interest Payable Current | 3422000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Liabilities Current | 236083000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Net Cash Provided By Used In Financing Activities | 183000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Operating Expenses | 34283000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Other Assets Current | 656000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Other Assets Noncurrent | 41269000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Other Liabilities Noncurrent | 62009000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Other Noncash Income Expense | 1513000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Payments For Repurchase Of Common Stock | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Proceeds From Issuance Of Common Stock | 488000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Proceeds From Issuance Of Common Stock | 250000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Profit Loss | 36532000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Profit Loss | -46584000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Purchase And Sale Of Other Investments Managed By Isp Fund Lp | -3414000.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 88632000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20250331 | Sale Of Equity Investments Managed By Isp Fund Lp | 19939000.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20240331 | Treasury Stock Value Acquired Cost Method | 6000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20241231 | Accounts Receivable Net | 20392000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Accounts Receivable Net | 600000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Zai Lab; Type Of Arrangement= Amended Zai Agreement; | ||
| 0000950170-25-065765 | 20240331 | Accrued Interest Income Included In Long Term Investments | 799000.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20250331 | Accrued Interest Income Included In Long Term Investments | 0.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20250331 | Common Stock Shares Outstanding | 62771000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20250331 | Cost Of Goods And Services Sold | 8842000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20250331 | Earnings Per Share Diluted | -0.7400 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Goodwill | 17905000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Income Tax Expense Benefit | 8592000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Increase Decrease In Accounts Receivable | -3719000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Increase Decrease In Deferred Revenue | -290000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Liabilities Current | 234745000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Net Cash Provided By Used In Financing Activities | -9165000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Operating Income Loss | -10539000.0000 | USD | 1 | us-gaap/2024 | Consolidated Entities= Armata Pharmaceuticals Inc; | ||
| 0000950170-25-065765 | 20240331 | Payments For Repurchase Of Common Stock | 9569000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Payments To Acquire Marketable Securities | 34674000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0100 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Prepaid Expense And Other Assets Current | 21063000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Proceeds From Sale Of Property Plant And Equipment | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20231231 | Profit Loss | -19847000.0000 | USD | 1 | us-gaap/2024 | Consolidated Entities= Armata Pharmaceuticals Inc; | ||
| 0000950170-25-065765 | 20240331 | Profit Loss Shares | 0.0000 | shares | 1 | 0000950170-25-065765 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20250331 | Purchases Of Equity Investments Managed By Isp Fund Lp | 0.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20241231 | Receivables Long Term Contracts Or Programs | 65974000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Receivables Long Term Contracts Or Programs | 61263000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Research And Development Expense | 3878000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 77499000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 77499000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Product Or Service= License And Other Revenue; | ||
| 0000950170-25-065765 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 30279000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product; | ||
| 0000950170-25-065765 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 57807000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Royalty; | ||
| 0000950170-25-065765 | 20240331 | Sale Of Equity Investments Managed By Isp Fund Lp | 5342000.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20250331 | Share Based Compensation | 2147000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -393829000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-065765 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 703681000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 691159000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -48381000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-065765 | 20240331 | Stock Issued During Period Value Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-065765 | 20250331 | Stock Issued During Period Value Share Based Compensation | 182000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-065765 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 62709000.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Accounts Receivable Net | 1600000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Zai Lab; Type Of Arrangement= Amended Zai Agreement; | ||
| 0000950170-25-065765 | 20250331 | Accrued Income Taxes Current | 1542000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Additional Paid In Capital Common Stock | 692329000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Additional Paid In Capital Common Stock | 694658000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-065765 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-065765 | 20240331 | Amortization Of Capitalized Fees And Depreciation Of Property And Equipment | 3510000.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20240331 | Amortization Of Intangible Assets | 6440000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Assets | 1301060000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Assets | 174800000.0000 | USD | 0 | us-gaap/2024 | Consolidated Entities= Isp Fund Lp; | ||
| 0000950170-25-065765 | 20250331 | Capitalized Contract Cost Amortization | 3456000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Royalty; Related Party Transactions By Related Party= G S K; | ||
| 0000950170-25-065765 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-065765 | 20241231 | Common Stock Shares Issued | 62665000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20231231 | Common Stock Shares Outstanding | 63307000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20241231 | Common Stock Shares Outstanding | 62665000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20250331 | Common Stock Shares Outstanding | 62771000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Cost Of Goods And Services Sold | 8842000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product; | ||
| 0000950170-25-065765 | 20241231 | Current Portion Of I S P Fund Investments | 107532000.0000 | USD | 0 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20241231 | Deferred Income Tax Assets Net | 12054000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20220630 | Goodwill | 11500000.0000 | USD | 0 | us-gaap/2024 | Consolidated Entities= Entasis Therapeutics Holdings Inc; | ||
| 0000950170-25-065765 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | 45124000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Increase Decrease In Accrued Liabilities | -4809000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Increase Decrease In Inventories | 9153000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Intangible Assets Net Excluding Goodwill | 201958000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Interest And Dividend Income Operating | 4399000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20240331 | Interest Expense | 5851000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20250331 | Interest Payable Current | 833000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Inventory Fair Value Step Up Adjustment Included In Cost Of Product Sales | 6843000.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20250331 | Inventory Net | 41479000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Long Term Debt Noncurrent | 256316000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Net Cash Provided By Used In Investing Activities | -43038000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Other Nonoperating Income Expense | -996000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-065765 | 20240331 | Payments Related To Tax Withholding For Share Based Compensation | 84000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Payments Related To Tax Withholding For Share Based Compensation | 67000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Profit Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-065765 | 20250331 | Property Plant And Equipment Net | 483000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Purchase And Sale Of Other Investments Managed By Isp Fund Lp | 19939000.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20241231 | Retained Earnings Accumulated Deficit | -1797000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 58415000.0000 | USD | 1 | us-gaap/2024 | Related Party Transactions By Related Party= G S K; | ||
| 0000950170-25-065765 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 628000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -1797000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-065765 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 646905000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Stock Issued During Period Shares Share Based Compensation | 0.0000 | shares | 1 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-065765 | 20240331 | Treasury Stock Shares Acquired | 634000.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20250331 | Profit Loss | -46584000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-065765 | 20241231 | Property Plant And Equipment Net | 514000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Purchases Of Equity Investments Managed By Isp Fund Lp | 8756000.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20250331 | Research And Development Expense | 1345000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; Product Or Service= Internal Expenses; | ||
| 0000950170-25-065765 | 20231231 | Revenue From Contract With Customer Excluding Assessed Tax | 1528000.0000 | USD | 1 | us-gaap/2024 | Consolidated Entities= Armata Pharmaceuticals Inc; | ||
| 0000950170-25-065765 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 19084000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product; | ||
| 0000950170-25-065765 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 58415000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Royalty; | ||
| 0000950170-25-065765 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 546000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= License And Other Revenue; | ||
| 0000950170-25-065765 | 20240331 | Selling General And Administrative Expense | 30405000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 628000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20240331 | Stock Issued During Period Shares Share Based Compensation | 124000.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20231231 | Treasury Stock Common Shares | 32005000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-065765 | 20240331 | Treasury Stock Value Acquired Cost Method | 9659000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-065765 | 20240331 | Treasury Stock Value Acquired Cost Method | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-065765 | 20250331 | Accrued Liabilities And Other Liabilities | 30664000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Accrued Income Taxes Current | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Accounts Payable Current | 2132000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Accounts Receivable Net | 600000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Zai Lab; Type Of Arrangement= Interim Supply Agreement; | ||
| 0000950170-25-065765 | 20250331 | Adjustments To Additional Paid In Capital Share Based Compensation Requisite Service Period Recognition Shares | 0.0000 | shares | 1 | 0000950170-25-065765 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 2147000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 2147000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-065765 | 20250331 | Amortization Of Financing Costs And Discounts | 541000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Assets | 255700000.0000 | USD | 0 | us-gaap/2024 | Consolidated Entities= Isp Fund Lp; | ||
| 0000950170-25-065765 | 20250331 | Assets | 1254390000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Cash And Cash Equivalents At Carrying Value | 319090000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 178357000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -15156000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Common Stock Shares Authorized | 200000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Common Stock Shares Outstanding | 62665000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Common Stock Value | 627000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Deferred Income Tax Expense Benefit | 3244000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Deferred Income Tax Expense Benefit | -240000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Equity Method Investment | 52293000.0000 | USD | 0 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20220831 | Goodwill | 6400000.0000 | USD | 0 | us-gaap/2024 | Business Acquisition= La Jolla Pharmaceutical Company; | ||
| 0000950170-25-065765 | 20250331 | Income Loss From Equity Method Investments | -13549000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Income Tax Expense Benefit | 7995000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Increase Decrease In Accounts Receivable | -315000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Increase Decrease In Deferred Revenue | -124000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Increase Decrease In Due From Related Parties Current | -7750000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Increase Decrease In Interest Payable Net | -2589000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Increase Decrease In Other Operating Assets | -551000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Increase Decrease In Prepaid Expense | -5079000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Increase Decrease In Prepaid Expense | -5649000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Inventory Fair Value Step Up Adjustment Included In Cost Of Product Sales | 244000.0000 | USD | 1 | 0000950170-25-065765 | |||
| 0000950170-25-065765 | 20250331 | Operating Expenses | 31887000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Operating Income Loss | 25805000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20250331 | Other Noncash Income Expense | -799000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Profit Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-065765 | 20240331 | Research And Development Expense | 1649000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; Product Or Service= External Services; | ||
| 0000950170-25-065765 | 20250331 | Research And Development Expense | 4396000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20241231 | Revenue From Contract With Customer Excluding Assessed Tax | 1235000.0000 | USD | 1 | us-gaap/2024 | Consolidated Entities= Armata Pharmaceuticals Inc; | ||
| 0000950170-25-065765 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 57807000.0000 | USD | 1 | us-gaap/2024 | Related Party Transactions By Related Party= G S K; | ||
| 0000950170-25-065765 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 674955000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-065765 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1085539000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-065765 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 692329000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-065765 | 20240331 | Stock Issued During Period Value Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-065765 | 20250331 | Stock Issued During Period Value Share Based Compensation | 1000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-065765 | 20240331 | Treasury Stock Common Shares | 32005000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-065765 | 20240331 | Treasury Stock Value Acquired Cost Method | 9665000.0000 | USD | 1 | us-gaap/2024 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Accounts Receivable | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Capitalized Contract Cost Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Capitalized Contract Cost, Amortization | Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Increase Decrease In Interest Payable Net | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Interest Payable, Net | The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Current Portion Of I S P Fund Investments | 0000950170-25-065765 | 1 | 0 | monetary | I | D | Current Portion Of ISP Fund Investments | Current portion of ISP Fund investments |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Including Portion Attributable to Noncontrolling Interest | Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Deferred Income Tax Assets Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Deferred Income Tax Assets, Net | Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. |
| Deferred Revenue Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Deferred Revenue, Current | Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Increase Decrease In Accrued Income Taxes Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Income Taxes Payable | The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. |
| Accrued Interest Income Included In Long Term Investments | 0000950170-25-065765 | 1 | 0 | monetary | D | D | Accrued Interest Income Included in Long-term Investments | Accrued interest income included in long-term investments. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Debt Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Debt, Current | Amount of debt and lease obligation, classified as current. |
| Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Stock Issued During Period Value Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | C | Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture | Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Adjustments To Additional Paid In Capital Share Based Compensation Requisite Service Period Recognition Shares | 0000950170-25-065765 | 1 | 0 | shares | D | Adjustments To Additional Paid In Capital Share based Compensation Requisite Service Period Recognition Shares | Adjustments to additional paid in capital share based compensation requisite service period recognition shares. | |
| Accounts Receivable Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. |
| Accrued Liabilities And Other Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities and Other Liabilities | Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Cost Of Goods And Services Sold | us-gaap/2024 | 0 | 0 | monetary | D | D | Cost of Goods and Services Sold | The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Gross Profit | us-gaap/2024 | 0 | 0 | monetary | D | C | Gross Profit | Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. |
| Increase Decrease In Prepaid Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense | The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. |
| Interest Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Interest Expense, Operating and Nonoperating | Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. |
| Interest Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Interest Payable, Current | Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Operating Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Increase Decrease In Other Operating Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Other Operating Assets | Amount of increase (decrease) in operating assets classified as other. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Preferred Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Issued | Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. | |
| Selling General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Selling, General and Administrative Expense | The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Amortization Of Capitalized Fees And Depreciation Of Property And Equipment | 0000950170-25-065765 | 1 | 0 | monetary | D | D | Amortization of Capitalized Fees and Depreciation of Property and Equipment | Amortization of capitalized fees and depreciation of property and equipment. |
| Purchases Of Equity Investments Managed By Isp Fund Lp | 0000950170-25-065765 | 1 | 0 | monetary | D | C | Purchases of Equity Investments Managed by Isp Fund Lp | Purchases of Equity Investments Managed by Isp Fund Lp |
| Amortization Of Financing Costs And Discounts | us-gaap/2024 | 0 | 0 | monetary | D | D | Amortization of Debt Issuance Costs and Discounts | Amount of amortization expense attributable to debt discount (premium) and debt issuance costs. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Increase Decrease In Due From Related Parties Current | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Due from Related Parties, Current | The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence. |
| Increase Decrease In Inventories | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Inventories | The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. |
| Other Noncash Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Noncash Income (Expense) | Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. |
| Preferred Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Proceeds From Sale Of Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Sale of Property, Plant, and Equipment | The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. |
| Profit Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Receivables Long Term Contracts Or Programs | us-gaap/2024 | 0 | 0 | monetary | I | D | Receivables, Long-Term Contracts or Programs | Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date. |
| Treasury Stock Shares Acquired | us-gaap/2024 | 0 | 0 | shares | D | Treasury Stock, Shares, Acquired | Number of shares that have been repurchased during the period and are being held in treasury. | |
| Accrued Income Taxes Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Income Taxes, Current | Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. |
| Deferred Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Deferred Income Tax Expense (Benefit) | Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. |
| Employee Related Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Employee-related Liabilities, Current | Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Goodwill | Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. |
| Intangible Assets Net Excluding Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Intangible Assets, Net (Excluding Goodwill) | Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. |
| Long Term Investments | us-gaap/2024 | 0 | 0 | monetary | I | D | Long-Term Investments | The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Operating Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Current | Amount of current assets classified as other. |
| Other Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Noncurrent | Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Income Loss From Equity Method Investments | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Equity Method Investments | Amount of income (loss) for proportionate share of equity method investee's income (loss). |
| Inventory Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Inventory, Net | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Increase Decrease In Accounts Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Purchase And Sale Of Other Investments Managed By Isp Fund Lp | 0000950170-25-065765 | 1 | 0 | monetary | D | C | Purchase and sale of other investments managed by ISP FUND LP | Purchase and sale of other investments managed by ISP FUND LP |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Additional Paid In Capital Common Stock | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital, Common Stock | Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. |
| Amortization Of Intangible Assets | us-gaap/2024 | 0 | 0 | monetary | D | D | Amortization of Intangible Assets | The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. |
| Capitalized Contract Cost Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Capitalized Contract Cost, Net | Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Interest And Dividend Income Operating | us-gaap/2024 | 0 | 0 | monetary | D | C | Interest and Dividend Income, Operating | Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein. |
| Interest Paid Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Interest Paid, Excluding Capitalized Interest, Operating Activities | Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Payments For Repurchase Of Common Stock | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments for Repurchase of Common Stock | The cash outflow to reacquire common stock during the period. |
| Payments Related To Tax Withholding For Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | C | Payment, Tax Withholding, Share-Based Payment Arrangement | Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Equity Method Investment | 0000950170-25-065765 | 1 | 0 | monetary | I | D | Equity Method Investment | Equity method investment. |
| Gain Loss On Other Investments | 0000950170-25-065765 | 1 | 0 | monetary | D | C | Gain (Loss) on Other Investments | Gain loss on other investments. |
| Sale Of Equity Investments Managed By Isp Fund Lp | 0000950170-25-065765 | 1 | 0 | monetary | D | D | Sale of equity investments managed by ISP FUND LP | Sale of equity investments managed by ISP FUND LP |
| Unrealized Other Gain Loss On Investments | 0000950170-25-065765 | 1 | 0 | monetary | D | C | Unrealized Other Gain Loss on Investments | Unrealized other gain loss on investments |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. | |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Other Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Payments To Acquire Marketable Securities | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Marketable Securities | Amount of cash outflow for purchase of marketable security. |
| Preferred Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Preferred Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Outstanding | Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. | |
| Proceeds From Issuance Of Common Stock | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Issuance of Common Stock | The cash inflow from the additional capital contribution to the entity. |
| Amortization Of Acquired Intangible Assets | 0000950170-25-065765 | 1 | 0 | monetary | D | D | Amortization of Acquired Intangible Assets | Amortization of acquired intangible assets. |
| Inventory Fair Value Step Up Adjustment Included In Cost Of Product Sales | 0000950170-25-065765 | 1 | 0 | monetary | D | D | Inventory Fair Value Step Up Adjustment Included In Cost Of Product Sales | Inventory fair value step-up adjustment included in cost of product sales. |
| Profit Loss Shares | 0000950170-25-065765 | 1 | 0 | shares | D | Profit Loss Shares | Profit Loss Shares | |
| Accrued Income Taxes Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Income Taxes, Noncurrent | Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent. |
| Increase Decrease In Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accrued Liabilities | The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. |
| Increase Decrease In Deferred Revenue | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Deferred Revenue | Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. |
| Long Term Debt Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Long-Term Debt, Excluding Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Stock Issued During Period Shares Share Based Compensation | us-gaap/2024 | 0 | 0 | shares | D | Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture | Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). | |
| Treasury Stock Common Shares | us-gaap/2024 | 0 | 0 | shares | I | Treasury Stock, Common, Shares | Number of previously issued common shares repurchased by the issuing entity and held in treasury. | |
| Treasury Stock Value Acquired Cost Method | us-gaap/2024 | 0 | 0 | monetary | D | D | Treasury Stock, Value, Acquired, Cost Method | Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0000950170-25-065765 | 2 | 3 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0000950170-25-065765 | 2 | 4 | BS | 0 | H | Accounts Receivable Net | us-gaap/2024 | Accounts receivable | 0 |
| 0000950170-25-065765 | 2 | 5 | BS | 0 | H | Receivables Long Term Contracts Or Programs | us-gaap/2024 | Receivables from collaboration arrangement | 0 |
| 0000950170-25-065765 | 2 | 6 | BS | 0 | H | Inventory Net | us-gaap/2024 | Inventory | 0 |
| 0000950170-25-065765 | 2 | 7 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid expenses | 0 |
| 0000950170-25-065765 | 2 | 8 | BS | 0 | H | Current Portion Of I S P Fund Investments | 0000950170-25-065765 | Current portion of ISP Fund investments | 0 |
| 0000950170-25-065765 | 2 | 9 | BS | 0 | H | Other Assets Current | us-gaap/2024 | Other current assets | 0 |
| 0000950170-25-065765 | 2 | 10 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0000950170-25-065765 | 2 | 11 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Property and equipment, net | 0 |
| 0000950170-25-065765 | 2 | 12 | BS | 0 | H | Equity Method Investment | 0000950170-25-065765 | Equity method investments | 0 |
| 0000950170-25-065765 | 2 | 13 | BS | 0 | H | Long Term Investments | us-gaap/2024 | Equity and long-term investments | 0 |
| 0000950170-25-065765 | 2 | 14 | BS | 0 | H | Capitalized Contract Cost Net | us-gaap/2024 | Capitalized fees paid, net | 0 |
| 0000950170-25-065765 | 2 | 15 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2024 | Right-of-use assets | 0 |
| 0000950170-25-065765 | 2 | 16 | BS | 0 | H | Goodwill | us-gaap/2024 | Goodwill | 0 |
| 0000950170-25-065765 | 2 | 17 | BS | 0 | H | Intangible Assets Net Excluding Goodwill | us-gaap/2024 | Intangible assets | 0 |
| 0000950170-25-065765 | 2 | 18 | BS | 0 | H | Deferred Income Tax Assets Net | us-gaap/2024 | Deferred tax assets, net | 0 |
| 0000950170-25-065765 | 2 | 19 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2024 | Other assets | 0 |
| 0000950170-25-065765 | 2 | 20 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0000950170-25-065765 | 2 | 23 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0000950170-25-065765 | 2 | 24 | BS | 0 | H | Employee Related Liabilities Current | us-gaap/2024 | Accrued personnel-related expenses | 0 |
| 0000950170-25-065765 | 2 | 25 | BS | 0 | H | Interest Payable Current | us-gaap/2024 | Accrued interest payable | 0 |
| 0000950170-25-065765 | 2 | 26 | BS | 0 | H | Deferred Revenue Current | us-gaap/2024 | Deferred revenue | 0 |
| 0000950170-25-065765 | 2 | 27 | BS | 0 | H | Debt Current | us-gaap/2024 | Convertible subordinated notes due 2025, net of issuance costs | 0 |
| 0000950170-25-065765 | 2 | 28 | BS | 0 | H | Accrued Income Taxes Current | us-gaap/2024 | Income Taxes Payable | 0 |
| 0000950170-25-065765 | 2 | 29 | BS | 0 | H | Accrued Liabilities And Other Liabilities | us-gaap/2024 | Other accrued liabilities | 0 |
| 0000950170-25-065765 | 2 | 30 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0000950170-25-065765 | 2 | 31 | BS | 0 | H | Long Term Debt Noncurrent | us-gaap/2024 | Long-term debt, net of discount and issuance costs | 0 |
| 0000950170-25-065765 | 2 | 32 | BS | 0 | H | Other Liabilities Noncurrent | us-gaap/2024 | Other long-term liabilities | 0 |
| 0000950170-25-065765 | 2 | 33 | BS | 0 | H | Accrued Income Taxes Noncurrent | us-gaap/2024 | Income tax payable, long-term | 0 |
| 0000950170-25-065765 | 2 | 34 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and contingencies (Note 12) | 0 |
| 0000950170-25-065765 | 2 | 36 | BS | 0 | H | Preferred Stock Value | us-gaap/2024 | Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding | 0 |
| 0000950170-25-065765 | 2 | 37 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock: $0.01 par value, 200,000 shares authorized, 62,771 and 62,665 issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 0 |
| 0000950170-25-065765 | 2 | 38 | BS | 0 | H | Additional Paid In Capital Common Stock | us-gaap/2024 | Additional paid-in capital | 0 |
| 0000950170-25-065765 | 2 | 39 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0000950170-25-065765 | 2 | 40 | BS | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Total stockholders' equity | 0 |
| 0000950170-25-065765 | 2 | 41 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders' equity | 0 |
| 0000950170-25-065765 | 3 | 1 | BS | 1 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | Preferred stock, par value (in dollars per share) | 0 |
| 0000950170-25-065765 | 3 | 2 | BS | 1 | H | Preferred Stock Shares Authorized | us-gaap/2024 | Preferred stock, shares authorized | 0 |
| 0000950170-25-065765 | 3 | 3 | BS | 1 | H | Preferred Stock Shares Issued | us-gaap/2024 | Preferred stock, shares issued | 0 |
| 0000950170-25-065765 | 3 | 4 | BS | 1 | H | Preferred Stock Shares Outstanding | us-gaap/2024 | Preferred stock, shares outstanding | 0 |
| 0000950170-25-065765 | 3 | 5 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value (in dollars per share) | 0 |
| 0000950170-25-065765 | 3 | 6 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized | 0 |
| 0000950170-25-065765 | 3 | 7 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares issued | 0 |
| 0000950170-25-065765 | 3 | 8 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares outstanding | 0 |
| 0000950170-25-065765 | 4 | 9 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | Total revenue | 0 |
| 0000950170-25-065765 | 4 | 10 | IS | 0 | H | Cost Of Goods And Services Sold | us-gaap/2024 | Cost of products sold (inclusive of amortization of inventory fair value adjustments) | 0 |
| 0000950170-25-065765 | 4 | 11 | IS | 0 | H | Amortization Of Acquired Intangible Assets | 0000950170-25-065765 | Amortization of acquired intangible assets | 0 |
| 0000950170-25-065765 | 4 | 12 | IS | 0 | H | Gross Profit | us-gaap/2024 | Gross profit | 0 |
| 0000950170-25-065765 | 4 | 14 | IS | 0 | H | Selling General And Administrative Expense | us-gaap/2024 | Selling, general and administrative | 0 |
| 0000950170-25-065765 | 4 | 15 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0000950170-25-065765 | 4 | 16 | IS | 0 | H | Operating Expenses | us-gaap/2024 | Total operating expenses | 0 |
| 0000950170-25-065765 | 4 | 17 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Income from operations | 0 |
| 0000950170-25-065765 | 4 | 18 | IS | 0 | H | Income Loss From Equity Method Investments | us-gaap/2024 | Changes in fair values of equity method investments, net | 0 |
| 0000950170-25-065765 | 4 | 19 | IS | 0 | H | Gain Loss On Other Investments | 0000950170-25-065765 | Changes in fair values of equity and long-term investments, net | 0 |
| 0000950170-25-065765 | 4 | 20 | IS | 0 | H | Interest And Dividend Income Operating | us-gaap/2024 | Interest and dividend income | 0 |
| 0000950170-25-065765 | 4 | 21 | IS | 0 | H | Interest Expense | us-gaap/2024 | Interest expense | 1 |
| 0000950170-25-065765 | 4 | 22 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2024 | Other expense, net | 0 |
| 0000950170-25-065765 | 4 | 23 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | Income (loss) before income taxes | 0 |
| 0000950170-25-065765 | 4 | 24 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2024 | Income tax expense, net | 1 |
| 0000950170-25-065765 | 4 | 25 | IS | 0 | H | Profit Loss | us-gaap/2024 | Net income (loss) and comprehensive income (loss) | 0 |
| 0000950170-25-065765 | 4 | 27 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Basic | 0 |
| 0000950170-25-065765 | 4 | 28 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Diluted | 0 |
| 0000950170-25-065765 | 4 | 30 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Basic | 0 |
| 0000950170-25-065765 | 4 | 31 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Diluted | 0 |
| 0000950170-25-065765 | 5 | 9 | IS | 1 | H | Capitalized Contract Cost Amortization | us-gaap/2024 | Amortization of capitalized fees paid | 0 |
| 0000950170-25-065765 | 6 | 9 | EQ | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Balance | 0 |
| 0000950170-25-065765 | 6 | 10 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Balance (in shares) | 0 |
| 0000950170-25-065765 | 6 | 11 | EQ | 0 | H | Treasury Stock Common Shares | us-gaap/2024 | Treasury stock balance (in shares) | 0 |
| 0000950170-25-065765 | 6 | 12 | EQ | 0 | H | Stock Issued During Period Value Share Based Compensation | us-gaap/2024 | Exercise of stock options and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding | 0 |
| 0000950170-25-065765 | 6 | 13 | EQ | 0 | H | Stock Issued During Period Shares Share Based Compensation | us-gaap/2024 | Exercise of stock options and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares) | 0 |
| 0000950170-25-065765 | 6 | 14 | EQ | 0 | H | Treasury Stock Value Acquired Cost Method | us-gaap/2024 | Repurchase of common stock | 1 |
| 0000950170-25-065765 | 6 | 15 | EQ | 0 | H | Treasury Stock Shares Acquired | us-gaap/2024 | Repurchase of common stock (in shares) | 1 |
| 0000950170-25-065765 | 6 | 16 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Stock-based compensation | 0 |
| 0000950170-25-065765 | 6 | 17 | EQ | 0 | H | Adjustments To Additional Paid In Capital Share Based Compensation Requisite Service Period Recognition Shares | 0000950170-25-065765 | Stock-based compensation (in shares) | 0 |
| 0000950170-25-065765 | 6 | 18 | EQ | 0 | H | Profit Loss | us-gaap/2024 | Net income (loss) | 0 |
| 0000950170-25-065765 | 6 | 19 | EQ | 0 | H | Profit Loss Shares | 0000950170-25-065765 | Net Income (loss) (in shares) | 0 |
| 0000950170-25-065765 | 6 | 20 | EQ | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Balance | 0 |
| 0000950170-25-065765 | 6 | 21 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Balance (in shares) | 0 |
| 0000950170-25-065765 | 6 | 22 | EQ | 0 | H | Treasury Stock Common Shares | us-gaap/2024 | Treasury stock balance (in shares) | 0 |
| 0000950170-25-065765 | 7 | 2 | CF | 0 | H | Profit Loss | us-gaap/2024 | Net income (loss) | 0 |
| 0000950170-25-065765 | 7 | 4 | CF | 0 | H | Deferred Income Tax Expense Benefit | us-gaap/2024 | Deferred income taxes | 0 |
| 0000950170-25-065765 | 7 | 5 | CF | 0 | H | Amortization Of Capitalized Fees And Depreciation Of Property And Equipment | 0000950170-25-065765 | Amortization of capitalized fees and depreciation of property and equipment | 0 |
| 0000950170-25-065765 | 7 | 6 | CF | 0 | H | Amortization Of Intangible Assets | us-gaap/2024 | Amortization of acquired intangible assets | 0 |
| 0000950170-25-065765 | 7 | 7 | CF | 0 | H | Inventory Fair Value Step Up Adjustment Included In Cost Of Product Sales | 0000950170-25-065765 | Inventory fair value step-up adjustment included in cost of products sold | 0 |
| 0000950170-25-065765 | 7 | 8 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock-based compensation | 0 |
| 0000950170-25-065765 | 7 | 9 | CF | 0 | H | Amortization Of Financing Costs And Discounts | us-gaap/2024 | Amortization of debt discount and issuance costs | 0 |
| 0000950170-25-065765 | 7 | 10 | CF | 0 | H | Income Loss From Equity Method Investments | us-gaap/2024 | Changes in fair values of equity method investments, net | 1 |
| 0000950170-25-065765 | 7 | 11 | CF | 0 | H | Unrealized Other Gain Loss On Investments | 0000950170-25-065765 | Changes in fair values of equity and long-term investments, net | 1 |
| 0000950170-25-065765 | 7 | 12 | CF | 0 | H | Other Noncash Income Expense | us-gaap/2024 | Other non-cash items | 1 |
| 0000950170-25-065765 | 7 | 14 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2024 | Accounts receivable | 1 |
| 0000950170-25-065765 | 7 | 15 | CF | 0 | H | Increase Decrease In Due From Related Parties Current | us-gaap/2024 | Receivables from collaboration arrangement | 1 |
| 0000950170-25-065765 | 7 | 16 | CF | 0 | H | Increase Decrease In Inventories | us-gaap/2024 | Inventory | 1 |
| 0000950170-25-065765 | 7 | 17 | CF | 0 | H | Increase Decrease In Prepaid Expense | us-gaap/2024 | Prepaid expenses | 1 |
| 0000950170-25-065765 | 7 | 18 | CF | 0 | H | Increase Decrease In Other Operating Assets | us-gaap/2024 | Other assets | 1 |
| 0000950170-25-065765 | 7 | 19 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2024 | Accounts payable | 0 |
| 0000950170-25-065765 | 7 | 20 | CF | 0 | H | Increase Decrease In Accrued Liabilities | us-gaap/2024 | Accrued personnel-related expenses and other accrued liabilities | 0 |
| 0000950170-25-065765 | 7 | 21 | CF | 0 | H | Increase Decrease In Interest Payable Net | us-gaap/2024 | Accrued interest payable | 0 |
| 0000950170-25-065765 | 7 | 22 | CF | 0 | H | Increase Decrease In Accrued Income Taxes Payable | us-gaap/2024 | Income tax payable | 0 |
| 0000950170-25-065765 | 7 | 23 | CF | 0 | H | Increase Decrease In Deferred Revenue | us-gaap/2024 | Deferred revenue | 0 |
| 0000950170-25-065765 | 7 | 24 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash provided by operating activities | 0 |
| 0000950170-25-065765 | 7 | 26 | CF | 0 | H | Payments To Acquire Marketable Securities | us-gaap/2024 | Purchases of trading securities | 1 |
| 0000950170-25-065765 | 7 | 27 | CF | 0 | H | Purchases Of Equity Investments Managed By Isp Fund Lp | 0000950170-25-065765 | Purchases of equity investments managed by ISP Fund LP | 1 |
| 0000950170-25-065765 | 7 | 28 | CF | 0 | H | Sale Of Equity Investments Managed By Isp Fund Lp | 0000950170-25-065765 | Sales of equity investments managed by ISP Fund LP | 0 |
| 0000950170-25-065765 | 7 | 29 | CF | 0 | H | Purchase And Sale Of Other Investments Managed By Isp Fund Lp | 0000950170-25-065765 | Purchases and sales of other investments managed by ISP Fund LP, net | 1 |
| 0000950170-25-065765 | 7 | 30 | CF | 0 | H | Proceeds From Sale Of Property Plant And Equipment | us-gaap/2024 | Sale of property and equipment | 0 |
| 0000950170-25-065765 | 7 | 31 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash used in investing activities | 0 |
| 0000950170-25-065765 | 7 | 33 | CF | 0 | H | Payments For Repurchase Of Common Stock | us-gaap/2024 | Repurchase of common stock | 1 |
| 0000950170-25-065765 | 7 | 34 | CF | 0 | H | Payments Related To Tax Withholding For Share Based Compensation | us-gaap/2024 | Repurchase of shares to satisfy tax withholding | 1 |
| 0000950170-25-065765 | 7 | 35 | CF | 0 | H | Proceeds From Issuance Of Common Stock | us-gaap/2024 | Proceeds from issuances of common stock, net | 0 |
| 0000950170-25-065765 | 7 | 36 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash provided by (used in) financing activities | 0 |
| 0000950170-25-065765 | 7 | 37 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Net increase (decrease) in cash and cash equivalents | 0 |
| 0000950170-25-065765 | 7 | 38 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents at beginning of period | 0 |
| 0000950170-25-065765 | 7 | 39 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents at end of period | 0 |
| 0000950170-25-065765 | 7 | 41 | CF | 0 | H | Interest Paid Net | us-gaap/2024 | Cash paid for interest | 0 |
| 0000950170-25-065765 | 7 | 43 | CF | 0 | H | Accrued Interest Income Included In Long Term Investments | 0000950170-25-065765 | Accrued interest income converted to long-term investments | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |